Hernandez-Ruiz Eleazar, Alvarado-Ibarra Martha, Juan Lien-Chang Lourdes Esthela, Banda-Garcia Luisa, Aquino-Salgado Jorge Luis, Barragan-Ibanez Gabriel, Ramirez-Romero Eva Fabiola, Nolasco-Cancino Cesar, Herrera-Olivares Wilfrido, Morales-Adrian Javier de Jesus, Paredes-Lozano Eugenia Patricia, Espitia-Rios Maria Eugenia, Gonzalez Lopez-Elizalde Maria de Monserrat, Lopez-Arroyo Jose Luis, Trejo-Gomora Jorge Enrique, De la Pena-Celaya Jose Antonio, Alvarez-Vera Jose Luis, Arana-Luna Luara Luz, Martinez-Rios Annel, Resendiz-Olea Rodrigo, Rodriguez-Velasquez Lucero Jazmin, Zapata-Canto Nidia, Perez-Zuniga Juan Manuel
Servicio de Hematologia, Hospital Regional de Alta Especialidad, de Oaxaca, Oaxaca, Mexico.
Servicio de Hematologia, Centro Medico Nacional "20 de Noviembre", ISSSTE, Mexico City, Mexico.
World J Oncol. 2021 Feb;12(1):28-33. doi: 10.14740/wjon1351. Epub 2021 Feb 24.
There is no epidemiological registry in Mexico. The information about the epidemiology in our country is obtained by these types of studies, such as multicentric studies. A lot of improvements in the survival in non-Hodgkin lymphoma patients had occurred in the last 20 years. The access to treatment in these types of pathology could change the prognostic factors in Mexican Mestizos patients. The primary objective of the study was to learn what the most frequent histological varieties of non-Hodgkin lymphoma in Mexico are. The secondary objectives included clinical characteristics, treatments used, treatment response, disease-free survival and overall survival.
A retrospective, descriptive study of consecutive cases was carried out in 14 hospitals across 14 Mexican states with patients diagnosed with non-Hodgkin lymphoma using the World Health Organization (WHO) 2008 criteria. Inclusion criteria included: ≥ 18 years of age, male or female, any clinical stage at diagnosis, who had received any chemotherapy regimen, with a known outcome. Descriptive statistics was performed for all variables, and survival was assessed using Kaplan-Meier curves.
Totally, 609 patients were enrolled, of which 545 were B-cell lymphomas and 64 were T-cell lymphomas. Median ages were 61 and 50, respectively. B-cell lymphomas were more common in males with 52.1%, and 65.5% of T-cell lymphomas occurred in females. For B-cell lymphomas, the two most frequent histological subtypes were diffuse large B-cell lymphoma in 63.9%, followed by follicular lymphoma at 18%. Meanwhile, 50% of T-cell lymphomas were of the T/natural killer (NK) subtype, and 87.1% of the patients received a CHOP-like regimen. Radiotherapy was given to 31% of B-cell Lymphomas and 46.9% of T-cell lymphomas. Overall survival at 9 years was 84.6% for B-cell lymphomas, and 73.4% for T-cell lymphomas.
Diffuse large B-cell lymphoma constitutes the most frequent subtype for B-cell lymphomas in Mexico. The most frequent T-cell lymphoma is the NK/T histological subtype.
墨西哥没有流行病学登记系统。我国的流行病学信息是通过这类研究获得的，比如多中心研究。在过去20年里，非霍奇金淋巴瘤患者的生存率有了很大提高。对于这类疾病，治疗途径可能会改变墨西哥混血患者的预后因素。本研究的主要目的是了解墨西哥非霍奇金淋巴瘤最常见的组织学类型。次要目的包括临床特征、使用的治疗方法、治疗反应、无病生存期和总生存期。
对墨西哥14个州的14家医院中连续诊断为非霍奇金淋巴瘤的患者进行回顾性描述性研究，诊断采用世界卫生组织（WHO）2008年标准。纳入标准包括：年龄≥18岁，男女不限，诊断时处于任何临床分期，接受过任何化疗方案，且预后已知。对所有变量进行描述性统计，并使用Kaplan-Meier曲线评估生存率。
共纳入609例患者，其中545例为B细胞淋巴瘤，64例为T细胞淋巴瘤。中位年龄分别为61岁和50岁。B细胞淋巴瘤在男性中更为常见，占52.1%，而65.5%的T细胞淋巴瘤发生在女性中。对于B细胞淋巴瘤，两种最常见的组织学亚型是弥漫性大B细胞淋巴瘤，占63.9%，其次是滤泡性淋巴瘤，占18%。同时，50%的T细胞淋巴瘤为T/自然杀伤（NK）亚型，87.1%的患者接受了类似CHOP的方案。31%的B细胞淋巴瘤和46.9%的T细胞淋巴瘤接受了放疗。B细胞淋巴瘤9年总生存率为84.6%，T细胞淋巴瘤为73.4%。
弥漫性大B细胞淋巴瘤是墨西哥B细胞淋巴瘤最常见的亚型。最常见的T细胞淋巴瘤是NK/T组织学亚型。
